Kinetics of transperitoneal tissue-type plasminogen activator absorption

Fibrinolysis

Volumn 10, Issue 1, 1996, Pages 1-7

  Holmdahl, L ^a   Eriksson, E ^a   Rippe, B ^b   Risberg, B ^c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; FIBRINOLYSIS; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; RAT; TOPICAL DRUG ADMINISTRATION;

EID: 0029866303     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(05)80069-4     Document Type: Article

References (31)

1. Gervin A S, Puckett C L, Silver D. Serosal hypofibrinolysis. Am J Surg 1973; 125: 80-8.
2. Buckman R F, Sargent L, Gervin A S. The relationship of local depression of peritoneal flbrinolytic activity to adhesion formation. Clin Res 1975; 23: 15.
3. Raftery A T. Effect of peritoneal trauma on peritoneal fibrinolytic activity and intraperitoneal adhesion formation. Eur Surg Res 1981; 13: 397-401.
4. Thompson J N, Paterson Brown S, Harbourne T, Whawell S A, Kalodiki E, Dudley H A F. Reduced human peritoneal plasminogen activating activity: possible mechanism of adhesion formation. Br J Surg 1989; 76: 382-4.
5. Vipond M N, Whawell S A, Thompson J N, Dudley H A. Peritoneal fibrinolytic activity and intra-abdominal adhesions. Lancet 1990; 335: 1120-2.
6. Knightly J J, Agostino D, Cliffton E E. The effect of fibrinolysin and heparin on the formation of peritoneal adhesions. Surgery 1962; 52: 250-8.
7. Birkenfeld A, Schenker J G. The effect of urokinase in the prevention of intraperitoneal adhesions; role of blood in their formation. Ann Chir Gynaecol 1983; 72: 246-9.
8. James D C O, Ellis H, Hugh T B. The effect of streptokinase on experimental intraperitoneal adhesion formation. J Path Bact 1965; 90: 279-87.
9. Doody K J, Dunn R C, Buttram V C. Recombinant tissue plasminogen activator reduces adhesion formation in a rabbit uterine horn model. Fertil Steril 1989; 51: 509-12.
10. D̈rr P J, Vemer H M, Brommer E J P, Wülemsen W N P, Veldhuizen R W, Rolland R. Prevention of postoperative adhesions by tissue-type plasminogen activator (t-PA) in the rabbit. Eur J Obstet Gynecol Reprod Biol 1990; 37: 287-91.
11. Dünn R C, Buttram V C. Tissue-type plasminogen activator as an adjuvant for post surgical adhesions. Prog Clin Biol Res 1990; 358: 113-8.
12. Menzies D, Ellis H. The role of plasminogen activator in adhesion prevention. Surg Gynecol Obstet 1991; 172: 362-6.
13. Montz F J, Fowler J M, Wolff A J, Lacey S M, Mohler M. The ability of recombinant tissue plasminogen activator to inhibit post-radical pelvic surgery adhesions in the dog model. Am J Obstet Gynecol 1991; 165: 1539-42.
14. Holmdahl L, Al-Jabreen M, Risberg B. The role of fibrinolysis in the formation of postoperative adhesions. Wound Rep Reg 1994; 7: 171-6.
15. Wiseman D M, Kamp L, Linsky C B, Jochen R F, Pang R H L, Scholz P M. Fibrin lytic drugs prevent pericardial adhesions in the rabbit. J Surg Res 1992; 53: 362-8.
16. Orita H, Fukasawa M, Girgis W, diZerega G S. Inhibition of postsurgical adhesions in a standardized rabbit model: intraperitoneal treatment with tissue plasminogen activator. Int J Fertil 1991; 36: 172-7.
17. Dünn R C, Mohler M. Effects of varying days of plasminogen activator therapy on the prevention of postsurgical adhesions in a rabbit model. J Surg Res 1993; 54: 242-5.
18. Flessner M F, Dedrick R L, Schultz J S. Exchange of macromolecules between peritoneal cavity and plasma. Am J Physiol 1985; 240: H15-25.
19. Aune S. Transperitoneal exchange. Scand J Gastroent 1970; 5: 241-52.
20. Herman S, Schoenfeld R. Invariants in experimental data on linear kinetics and the formulation of models. J Appl Physiol 1956; 27: 1361-70.
21. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker Inc., 1982.
22. Korninger C, Stassen J M, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemost 1981; 46: 658-61.
23. Fuchs H E, Berger H, Pizzo S V. Catabolism of human tissue plasminogen activator in mice. Blood 1985; 65: 539-44.
24. Seifried E, Tanswell P, Rijken D C, Barret-Bergshoeff M M, Su C A P F, Kluft C. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzneimittelforschung 1988; 38: 318-22.
25. Verstraete M, Bounameaux H, Cock F, van de Werf F, Collen D. Pharmacokinetics and systematic fibrogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in human. J Pharmacol Exp Ther 1985; 235: 506-12.
26. Nilsson T, Wallen P, Mellbring G. In vivo metabolism of human tissue-type plasminogen activator. Scand J Haematol 1984; 33: 49-53.
27. Beebe D P, Aronson D L. Turnover of human tissue plasminogen activator (tPA) in rabbits. Thromb Res 1986; 43: 663-74.
28. Emeis J J, van den Hoogen C M, Jense D. Hepatic clearance of tissue-type plasminogen activator in rats. Thromb Haemost 1985; 54: 661-4.
29. Beebe D P. Binding of tissue plasminogen activator to human umbilical vein endothelial cells. Thromb Res 1987; 46: 241-54.
30. Hajjar K A, Hamel N M. Harpel peritoneal cavity. In: Nachman R L, ed. Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest 1987; 80: 1712-9.
31. Underwood M J, More R S, Gershlick A H, de Bono D P. Effect of locally applied tissue-type plasminogen activator on venous fibrinolytic activity: in vitro and in vivo investigations. Cardiovasc Res 1993; 27: 2270-3.